Phase I study of ICRF-159 (NSC-129943) in human solid tumors.
作者信息
Bellet R E, Mastrangelo M J, Dixon L M, Yarbro J W
出版信息
Cancer Chemother Rep. 1973 Apr;57(2):185-9.
PMID:4742498
Abstract
摘要
相似文献
1
Phase I study of ICRF-159 (NSC-129943) in human solid tumors.ICRF-159（NSC-129943）在人类实体瘤中的I期研究。
Cancer Chemother Rep. 1973 Apr;57(2):185-9.
2
Combined treatment of soft tissue and osteosarcomas by radiation and ICRF 159.软组织和骨肉瘤的放射治疗与ICRF 159联合治疗
Cancer. 1974 Oct;34(4):1040-5. doi: 10.1002/1097-0142(197410)34:4<1040::aid-cncr2820340413>3.0.co;2-5.
3
4
5
Enhancement of antitumor effectiveness of ICRF-159 (NSC-129943) against early L1210 leukemia by combination with cis-diamminedichloroplatinum (NSC-119875) or daunomycin (NSC-82151).通过与顺二氨二氯铂（NSC - 119875）或柔红霉素（NSC - 82151）联合使用增强ICRF - 159（NSC - 129943）对早期L1210白血病的抗肿瘤效果。
Cancer Chemother Rep 2. 1974 Mar;4(1):45-52.
6
[Clinical use of prospidine].[丙帕他莫的临床应用]
Vopr Onkol. 1970;16(8):36-41.
7
Vascular changes in tumours after treatment with ICRF 159.用ICRF 159治疗后肿瘤中的血管变化。
Br J Pharmacol. 1971 Oct;43(2):457P-458P.
8
Letter: ICRF 159.信函：国际癌症研究基金会159号
Lancet. 1974 Mar 30;1(7857):560. doi: 10.1016/s0140-6736(74)92736-6.
9
Phase II trial of ICRF-187 in non-small cell lung cancer.
Cancer Treat Rep. 1983 Mar;67(3):311-3.
10
Control of malignant metastases by ICRF l59.
Nature. 1969 Oct 18;224(5216):273-5. doi: 10.1038/224273a0.
引用本文的文献
1
ICRF-159 enhancement of radiation response in combined modality therapies. II. Differential responses of tumour and normal tissues.ICRF - 159在综合治疗中增强辐射反应。II. 肿瘤组织与正常组织的不同反应。
Br J Cancer. 1979 May;39(5):524-30. doi: 10.1038/bjc.1979.96.
Zotero 插件